A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy

Abstract

These data suggest that the novel TCR-targeting LMP1 might allow the potential design of T-cell-based immunotherapeutic strategies against EBV-positive malignancies.